Jvan Casarin1, Chao Song2, Francesco Multinu3, Serena Cappuccio3, Emelline Liu2, Kristina A Butler4, Gretchen E Glaser3, William A Cliby3, Carrie L Langstraat3, Fabio Ghezzi5, Alex Z Fu6, Andrea Mariani7. 1. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA; Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy. 2. Department of Global Health Economics and Outcome Research, Intuitive Surgical Inc, Sunnyvale, CA, USA. 3. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA. 4. Department of Medical and Surgical Gynecology and Division of Hematology and Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ, USA. 5. Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy. 6. Georgetown University Medical Center, Washington, DC. Dr Fu is now with Bristol-Myers Squibb, Lawrence Township, New Jersey, USA. 7. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA. Electronic address: mariani.andrea@mayo.edu.
Abstract
OBJECTIVE: To examine the effect of robotic-assisted surgery implementation for treatment of endometrial cancer in the United States on 30-day clinical outcomes and costs. METHODS: We retrospectively reviewed data of adult patients who underwent total hysterectomy for endometrial cancer in the US hospitals in Premier Healthcare Database between January 1, 2008 and September 30, 2015. We conducted trend analyses comparing the proportions of surgical approaches with the associated clinical outcomes and costs over the study period using Mann-Kendall tests. Clinical outcomes and costs of robotic-assisted surgery, laparoscopic and open surgery have been compared after propensity score 1:1 matching in the most recent 3 years (January 1, 2013-September 30, 2015). RESULTS: Of a total of 35,224 patients, use of robotic-assisted surgery increased from 9.48% to 56.82% while open surgery decreased from 70.4% to 28.1% over the study period. A 2.5% decrease in major complications (P < .001), a 2.9% decrease in minor complications (P = .001), and a 2.0% decrease 30-day readmissions (P = .001) was observed across all surgical approaches. Perioperative 30-day total cost slightly decreased from US $11,048 to US $10,322 (P = .08). Among propensity-score matched patients, robotic-assisted surgery was associated with shorter hospitalization than open surgery (median [interquartile range], 2.0 [2.0-3.0] vs 4.0 [3.0-6.0] days) and laparoscopic surgery (2.0 [2.0-3.0] vs 3.0 [2.0-4.0] days), fewer 30-day complications (20.1% vs 33.7%) (all P < .001), and comparable perioperative 30-day total costs (median [interquartile range], US $12,200 [US $9,509-US $16,341] vs US $12,018 [US $8,996-US $17,162]; P = .34) with open surgery. CONCLUSION: Robotic-assisted surgery facilitated the widespread diffusion of a minimally invasive approach nationally for endometrial cancer, with reduction of perioperative morbidity and no increase in overall treatment-related 30-day costs at national level.
OBJECTIVE: To examine the effect of robotic-assisted surgery implementation for treatment of endometrial cancer in the United States on 30-day clinical outcomes and costs. METHODS: We retrospectively reviewed data of adult patients who underwent total hysterectomy for endometrial cancer in the US hospitals in Premier Healthcare Database between January 1, 2008 and September 30, 2015. We conducted trend analyses comparing the proportions of surgical approaches with the associated clinical outcomes and costs over the study period using Mann-Kendall tests. Clinical outcomes and costs of robotic-assisted surgery, laparoscopic and open surgery have been compared after propensity score 1:1 matching in the most recent 3 years (January 1, 2013-September 30, 2015). RESULTS: Of a total of 35,224 patients, use of robotic-assisted surgery increased from 9.48% to 56.82% while open surgery decreased from 70.4% to 28.1% over the study period. A 2.5% decrease in major complications (P < .001), a 2.9% decrease in minor complications (P = .001), and a 2.0% decrease 30-day readmissions (P = .001) was observed across all surgical approaches. Perioperative 30-day total cost slightly decreased from US $11,048 to US $10,322 (P = .08). Among propensity-score matched patients, robotic-assisted surgery was associated with shorter hospitalization than open surgery (median [interquartile range], 2.0 [2.0-3.0] vs 4.0 [3.0-6.0] days) and laparoscopic surgery (2.0 [2.0-3.0] vs 3.0 [2.0-4.0] days), fewer 30-day complications (20.1% vs 33.7%) (all P < .001), and comparable perioperative 30-day total costs (median [interquartile range], US $12,200 [US $9,509-US $16,341] vs US $12,018 [US $8,996-US $17,162]; P = .34) with open surgery. CONCLUSION: Robotic-assisted surgery facilitated the widespread diffusion of a minimally invasive approach nationally for endometrial cancer, with reduction of perioperative morbidity and no increase in overall treatment-related 30-day costs at national level.
Authors: Peter A Argenta; Jordan Mattson; Colleen L Rivard; Elizabeth Luther; Alexandra Schefter; Rachel I Vogel Journal: Gynecol Oncol Date: 2022-03-18 Impact factor: 5.304
Authors: Paresh C Shah; Alexander de Groot; Robert Cerfolio; William C Huang; Kathy Huang; Chao Song; Yanli Li; Usha Kreaden; Daniel S Oh Journal: Surg Endosc Date: 2022-02-09 Impact factor: 3.453
Authors: Kristin Bixel; David A Barrington; Monica H Vetter; Adrian A Suarez; Ashley S Felix Journal: J Minim Invasive Gynecol Date: 2021-08-01 Impact factor: 4.137